financetom
Business
financetom
/
Business
/
Li Auto's Q2 Non-GAAP Earnings Decline, Revenue Increases
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Li Auto's Q2 Non-GAAP Earnings Decline, Revenue Increases
Aug 29, 2024 9:13 AM

05:27 AM EDT, 08/28/2024 (MT Newswires) -- Li Auto ( LI ) reported Q2 non-GAAP earnings Wednesday of 1.42 Chinese renminbi ($0.20) per diluted American depositary share, down from 2.58 renminbi a year earlier.

Analysts polled by Capital IQ expected 1.38 renminbi.

Revenue for the quarter ended June 30 was 31.68 billion renminbi, compared with 28.65 billion renminbi a year earlier.

Analysts surveyed by Capital IQ expected 31.59 billion renminbi.

The company said it expects Q3 revenue to be between 39.4 billion renminbi and 42.2 billion renminbi. Analysts surveyed by Capital IQ expect 39.41 billion renminbi.

Price: 21.28, Change: +0.06, Percent Change: +0.28

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Long-time CEO of NEOM goes as Saudi Arabia scales back mega-projects
Long-time CEO of NEOM goes as Saudi Arabia scales back mega-projects
Nov 12, 2024
By Nayera Abdallah and Pesha Magid DUBAI/RIYADH (Reuters) -Nadhmi al-Nasr, the long-time chief executive of the $500 billion NEOM mega-project at the heart of Saudi Arabia's drive to diversify away from oil, has departed, NEOM said on Tuesday without giving a reason. Crown Prince Mohammed bin Salman, known as MbS, has poured hundreds of billions of dollars into development projects...
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer
Nov 12, 2024
On Tuesday, Syndax Pharmaceuticals Inc ( SNDX ) revealed topline results from the relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML) cohort in the pivotal Phase 2 portion of the AUGMENT-101 trial of revumenib. The cohort met the primary endpoint with a complete remission (CR) plus CR with a partial hematological recovery (CRh) rate of 23% among the...
What's Going On With NIO Stock Today?
What's Going On With NIO Stock Today?
Nov 12, 2024
NIO Inc. ( NIO ) shares are trading lower on Tuesday. In fact, shares of U.S.-listed Chinese stocks are trading lower in possible reaction to President-elect Trump’s administration picks, which could raise concerns about a tougher China stance. According to Benzinga Pro, NIO stock has lost over 36% in the past year. Investors can gain exposure to the stock via Invesco Golden...
Plug Power Stock Slides On Q3 Earnings: Revenue Miss, EPS Miss, Soft Guidance And More
Plug Power Stock Slides On Q3 Earnings: Revenue Miss, EPS Miss, Soft Guidance And More
Nov 12, 2024
Plug Power Inc ( PLUG ) reported third-quarter financial results before the market opened on Tuesday. Here’s a look at the key metrics from the quarter. Q3 Earnings: Plug Power ( PLUG ) reported third-quarter revenue of $173.73 million, missing analyst estimates of $210.23 million. The company reported a quarterly loss of 25 cents per share, missing analyst estimates for...
Copyright 2023-2026 - www.financetom.com All Rights Reserved